Want to see GB:ABDX full AI Analyst Report?
ABDX Stock Chart & Stats
6.25 p
0.20 p(2.50%)
At close: 4:00 PM EST
6.25 p
0.20 p(2.50%)
Day’s Range― - ―
52-Week Range5.10 p - 13.00 p
Previous CloseN/A
Volume7.61K
Average Volume (3M)78.74K
Market Cap
£25.91M
Enterprise Value19.51M
Total Cash (Recent Filing)£3.71M
Total Debt (Recent Filing)£948.00K
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Nov 18, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,751,500
10 Day Avg. Volume45,332
30 Day Avg. Volume78,736
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£15.22M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit revenue growth indicates expanding demand and successful commercial execution. For a B2B diagnostics manufacturer, durable top-line expansion supports higher factory utilization, spreads fixed costs, and creates a larger addressable services pipeline that can underpin future margin recovery and scale advantages.
Contract Manufacturing B2B ModelA B2B contract development and manufacturing model yields recurring, volume-linked revenue and deeper customer relationships. This creates multi-year program visibility, steadier demand from large healthcare and diagnostic customers, and potential for long-term service margins as IP and scale embed the company in customers' supply chains.
Manageable LeverageRelatively low leverage and a moderate equity ratio give financial flexibility to invest in capacity, R&D, or absorb working capital swings. That balance sheet headroom reduces refinancing risk, enabling the company to pursue contract wins or scale manufacturing without immediate solvency pressure, a durable support for growth.
Bears Say
Unprofitable OperationsPersistent negative EBIT and net margins imply the business is not yet delivering sustainable profits from its operations. Over multiple quarters this constrains internal reinvestment, forces reliance on external capital, and raises execution risk for scaling; profitability is a fundamental prerequisite for long-term value creation.
Negative Operating Cash FlowNegative operating cash flow despite revenue growth signals poor conversion of sales into cash. This structural inefficiency pressures liquidity and increases dependency on financing to fund working capital and capex, weakening the firm's ability to self-fund growth and making it vulnerable during prolonged downturns.
Declining Gross MarginA falling gross margin points to margin compression from pricing pressure, rising input costs, or inefficiencies in manufacturing. For a contract manufacturer, continued margin erosion undermines the economics of volume growth and makes profitability contingent on either cost reductions or higher-margin contract wins, both of which take time to materialize.
Abingdon Health PLC News
ABDX FAQ
What was Abingdon Health PLC’s price range in the past 12 months?
Abingdon Health PLC lowest share price was 5.10 p and its highest was 13.00 p in the past 12 months.
What is Abingdon Health PLC’s market cap?
Abingdon Health PLC’s market cap is £25.91M.
When is Abingdon Health PLC’s upcoming earnings report date?
Abingdon Health PLC’s upcoming earnings report date is Nov 18, 2026 which is in 139 days.
How were Abingdon Health PLC’s earnings last quarter?
Abingdon Health PLC released its earnings results on Mar 17, 2026. The company reported -0.004 p earnings per share for the quarter, beating the consensus estimate of -0.006 p by 0.002 p.
Is Abingdon Health PLC overvalued?
According to Wall Street analysts Abingdon Health PLC’s price is currently Overvalued.
Does Abingdon Health PLC pay dividends?
Abingdon Health PLC does not currently pay dividends.
What is Abingdon Health PLC’s EPS estimate?
Abingdon Health PLC’s EPS estimate is <0.01.
How many shares outstanding does Abingdon Health PLC have?
Abingdon Health PLC has 252,751,500 shares outstanding.
What happened to Abingdon Health PLC’s price movement after its last earnings report?
Abingdon Health PLC reported an EPS of -0.004 p in its last earnings report, beating expectations of -0.006 p. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Abingdon Health PLC?
Currently, no hedge funds are holding shares in GB:ABDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abingdon Health PLC
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-acting diagnostic for COVID-19 IgG antibodies, alongside various nucleic acid lateral flow immunoassays. They also offer Seralite, a swift lateral flow test for accurately measuring kappa and lambda immunoglobulin free light chains in blood serum. Additionally, their AppDx technology converts any smartphone into an autonomous and adaptable lateral-flow reader. Beyond these offerings, the company provides expert services in lateral flow development and manufacturing, as well as advisory support to firms in the health tech industry. Abingdon Health Plc also engages in a collaborative and co-marketing partnership with Abcam plc.
Technical Analysis
Circassia Pharmaceuticals
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Renalytix
―
Options Prices
Currently, No data available
---